Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Spinal Fluid
Use
AP3B2 (adaptor protein 3 beta2)-IgG is a marker of an autoimmune disorder characterized by gait instability as the predominant neurologic presentation. Patients present with cerebellar, dorsal column, or sensory neuronal dysfunction. The test is useful for the differential diagnosis of mixed cerebellar and sensory ataxia and myeloneuropathy. Clinical improvement following treatment has been reported. AP3B2 autoimmunity appears rare and potentially treatable.
Special Instructions
This test is only orderable as part of a profile. For additional test ordering details, see MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.
Limitations
A negative result does not exclude neurological autoimmunity or cancer. The test's performance characteristics were developed by Mayo Clinic in a manner consistent with CLIA requirements. It is not cleared or approved by the US FDA, and improper specimen collection, handling, and inappropriate test selection can lead to diagnostic confusion.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 101907-4
- 101907-4
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
Not provided
Container
Sterile vial
Collection Instructions
Preferred container is vial number 1; any vial is acceptable.
Storage Instructions
Refrigerated (preferred): 28 days; Ambient: 72 hours; Frozen: 28 days.
Causes for Rejection
Gross hemolysis, gross lipemia, and gross icterus are causes for rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |